Board Questions on Mortality Improvement After Shocks

What the Board Should Be Asking About Mortality Assumptions Right Now

Board oversight of a reinsurer's mortality improvement assumptions tends to be light-touch in calm periods, and that is arguably fine when experience is stable and well understood. A structural shock changes that calculus.

Once there is documented, industry-acknowledged uncertainty about whether the mortality trend has genuinely returned to its pre-shock path, the assumption underlying pricing and reserves stops being a routine technical detail. It becomes something the board needs to actively govern, not passively receive as a line item in an actuarial report.

Why Should the Board Scrutinize This Assumption Directly?

Because mortality improvement assumptions drive pricing, reserving, and capital adequacy across the entire book, making them a genuine risk-appetite decision rather than a purely technical one.

A board that delegates this entirely to the actuarial function is effectively delegating a risk-appetite decision without realizing it. The assumption embedded in every treaty determines how much risk the company is actually taking on relative to what it is being paid, and how much capital is being held against that risk.

When that assumption is under genuine question following a structural shock, as documented by the industry's own actuarial research bodies, the board has a direct governance interest in understanding how management is handling that uncertainty, not just being told the number.

What Is the Single Most Important Question a Board Should Ask?

How long has it been since actual mortality experience was compared against the current assumption at a cohort level, and what did that comparison show.

This single question cuts through most of the ambiguity. If management cannot answer it with a specific, recent, cohort-level answer, that itself is the finding, since it means the organization is not running the kind of monitoring process needed to catch drift before it compounds.

If management can answer it, the follow-up questions become straightforward. What deviation, if any, was found, how many periods has it persisted, and what action, if any, has been taken or recommended in response.

How Can the Board Distinguish Caution From Overreaction?

By asking for the underlying data behind any proposed assumption change, specifically how many periods of consistent deviation support the recommendation, not just the headline conclusion.

A recommendation to change a major pricing or reserving assumption should never arrive at the board level without the supporting evidence attached. The board's role here is not to relitigate the actuarial analysis, but to confirm that the recommendation is grounded in a sustained, multi-period pattern rather than a single volatile quarter.

This distinction matters because both overreacting to noise and ignoring genuine signal carry real costs, a tension covered from the executive decision-making side in what reinsurance CEOs must decide about mortality improvement assumptions.

Should the Board Expect One Mortality Assumption or Several?

Several, since a single blended company-wide assumption can mask meaningfully different trends across product lines, age bands, and geographies.

Documented post-pandemic mortality data shows deviation concentrated unevenly, with younger cohorts carrying different cause-specific patterns than older ones. A board reviewing only a single blended assumption number has no way to see that kind of unevenly distributed shift, which means the questioning needs to go one level deeper than the headline figure to be genuinely useful as an oversight exercise.

How Should the Board Weigh This Against Rating Agency and Regulatory Expectations?

Rating agencies and regulators increasingly expect boards to demonstrate active oversight of assumption-setting, not just receive it, which makes documented board scrutiny a defensive asset as well as a governance best practice.

A board that can show a clear, dated trail of questions asked, evidence reviewed, and decisions made around mortality improvement assumptions is in a materially stronger position during a rating review or regulatory examination than one that can only point to an annual actuarial report signed off without much discussion, a scrutiny that extends to rated, index-linked instruments such as those discussed in catastrophe mortality bonds and pandemic risk. This is not a reason to turn board oversight into a compliance exercise, but it is a reason to keep the documentation habit tight, since the same record that supports good internal decision-making also supports the external conversations a reinsurer inevitably has to have after a structural shock draws outside scrutiny to the industry's assumptions.

How Should Board Discussion of This Topic Be Structured for Efficiency?

The most efficient format is a short, standing agenda item with a one-page cohort-level summary submitted in advance, reserving live discussion time for deviations and decisions rather than for reviewing raw data.

Boards that try to review mortality assumption detail from scratch in every meeting either rush the topic or let it consume disproportionate time relative to other agenda items. A better structure sends a concise, standardized one-page summary ahead of the meeting, covering the latest actual-to-expected results by cohort, any deviations flagged since the last meeting, and management's current recommendation, so the board's actual meeting time goes to questioning the recommendation rather than absorbing the underlying data for the first time.

This structure also creates a useful audit trail on its own, since a consistent, dated series of one-page summaries becomes exactly the kind of documented oversight record that matters to rating agencies and regulators, without requiring the board to treat every meeting as a full technical review.

Which Board Committee Should Own This, and How Should It Coordinate With Others?

The risk committee, or its equivalent, should own primary oversight of mortality improvement assumptions, coordinating explicitly with the audit committee on reserving implications and with any investment or finance committee on capital allocation consequences.

Splitting this topic entirely across committees without clear ownership tends to produce the worst outcome, where each committee assumes another is tracking the full picture and no single committee actually is. Naming the risk committee as the primary owner, with a standing requirement to report capital and reserving implications to the relevant sister committees rather than assuming those committees will independently pick up the thread, closes that coordination gap directly.

This structure also gives management a single, clear channel for escalation. Rather than deciding case by case which committee to brief on a given deviation, a defined primary owner with a defined coordination responsibility to other committees means the escalation path is already established well before any specific deviation requires using it, the same clear-ownership principle that applies to board oversight of anti-selection in digital life distribution.

What Capital Implication Should the Board Be Watching For?

Whether reserving assumptions have kept pace with any confirmed pricing assumption change, since a lag between the two can understate true capital needs.

Pricing and reserving assumptions are often reviewed on different cycles within the same organization, and that gap is exactly where governance risk hides. A board that confirms management has updated pricing assumptions in response to confirmed drift, without also confirming reserving assumptions reflect the same updated view, has only closed half of the exposure.

The capital adequacy question deserves to be asked explicitly and separately from the pricing question, not assumed to follow automatically.

The boards that handle this well are not the ones demanding perfection from their actuarial teams. They are the ones that have made mortality assumption monitoring a standing, documented agenda item during periods of confirmed uncertainty, with clear evidence requirements attached.

That way, any drift gets surfaced at the pace the underlying data actually moves rather than at the pace of a routine annual calendar.

Sources

• Society of Actuaries Research Institute: RPEC 2025 Mortality Improvement Update
• Munich Re: Group Life mortality trends, a post-pandemic perspective